TacticScaleWhat Yifeng Pharmacy Chain (益丰药房) Does & How It Makes Money (603939.SS)
Updated October 2026 · reflects Yifeng Pharmacy Chain's latest reported financials
Chinese pharmacy chain selling medicines and health products. It earns most of its money from the markup on medicines and health products sold in its own pharmacies, plus wholesale sales, supplies to franchise stores and online sales.
How Yifeng Pharmacy Chain makes money
It earns most of its money from the markup on medicines and health products sold in its own pharmacies, plus wholesale sales, supplies to franchise stores and online sales. Clinics, internet hospitals and chronic disease management bring in extra service revenue.
What Yifeng Pharmacy Chain does
Yifeng Pharmacy Chain, founded in 2001 and based in Changsha, runs retail pharmacies in China. It reports two segments, Retail and Wholesale. Its products range from Western and Chinese patent medicines and TCM herbal pieces to medical devices, health supplements, personal care items and health-related convenience goods. Beyond its own stores, the company sells through franchise distribution and e-commerce. It has also expanded into healthcare services such as chronic disease management, internet hospitals and clinics, along with medical project investment and medical technology development.
Products & services
- Retail pharmacy chain
- Western and Chinese patent medicines
- Traditional Chinese medicine herbal pieces
- Medical devices and health supplements
- Franchise distribution and e-commerce
- Internet hospitals and chronic disease management
益丰药房是做什么的？
益丰大药房连锁股份有限公司成立于2001年，总部位于湖南长沙，主要在中国经营药品零售业务，分为零售和批发两个业务板块。公司销售西药、中成药、中药饮片、医疗器械、保健品、个人护理用品以及健康相关的便利商品。 除了自营门店，公司还通过加盟和电商渠道销售，并开展慢病管理、互联网医院和诊所等医疗服务，同时涉及医疗项目投资和医疗技术开发。
What is Yifeng Pharmacy Chain worth?
On an owner-earnings DCF, Yifeng Pharmacy Chain's most-likely value is about ¥49 versus a recent price near ¥25 (49% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥23) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Yifan Pharmaceutical (002019.SZ) · Yixintang Pharmaceutical (002727.SZ) · Shijiazhuang Yiling Pharmaceutical (002603.SZ) · DaShenLin Pharmaceutical (603233.SS)